<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03192059</url>
  </required_header>
  <id_info>
    <org_study_id>2016-001569-97</org_study_id>
    <nct_id>NCT03192059</nct_id>
  </id_info>
  <brief_title>Study of Pembrolizumab, Radiation and Immune Modulatory Cocktail in Cervical/Uterine Cancer</brief_title>
  <acronym>PRIMMO</acronym>
  <official_title>A Phase II Investigation of Pembrolizumab (Keytruda) in Combination With Radiation and an Immune Modulatory Cocktail in Patients With Cervical and Uterine Cancer (PRIMMO Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kom Op Tegen Kanker</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Anticancer Fund, Belgium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Ghent</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase II study in patients with advanced and/refractory cervical cancer,&#xD;
      endometrial carcinoma or uterine sarcoma.&#xD;
&#xD;
      Patients will be treated with an immunomodulatory cocktail (Vitamin D, aspirin,&#xD;
      Cyclophosphamide and Lansoprazole), followed by pembrolizumab, combined with radiation. In&#xD;
      addition, patients will take Curcumin, a food supplement.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase II multi-center, open-label, non-randomized, 3-cohort study in patients with&#xD;
      advanced and/or refractory cervical cancer, endometrial carcinoma or uterine sarcoma.&#xD;
      Patients will be treated by an immunomodulatory cocktail (consisting of a daily intake of&#xD;
      2000 IU Vitamin D, 325 mg aspirin, 50 mg Cyclophosphamide and 180 or 30 mg Lansoprazole&#xD;
      alternating weekly), followed by pembrolizumab administered intravenously at 200 mg in 21-day&#xD;
      treatment cycles, combined with radiation (3x 8Gy in 48h-intervals). In addition, patients&#xD;
      will take Curcumin, a food supplement on a daily basis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2017</start_date>
  <completion_date type="Actual">June 30, 2021</completion_date>
  <primary_completion_date type="Actual">June 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate at week 26</measure>
    <time_frame>week 26</time_frame>
    <description>Efficacy (objective response rate) at week 26 according to immune related response criteria (irRC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent adverse events (Safety according to CTCAE4.0).</measure>
    <time_frame>up to 30 days post end of study treatment</time_frame>
    <description>The number of unmanageable dose limiting toxicities will be reported for the run-in period and the main trial. This analysis will be performed for both the Full Analysis Set (FAS; evaluable patiÃ«nts) and extended FAS (eFAS; all patients included in the trial).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>week 26</time_frame>
    <description>Objective response rate at week 26 according to RECIST criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best OR</measure>
    <time_frame>week 26</time_frame>
    <description>Best overall response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>up to 156 weeks</time_frame>
    <description>At weeks 26, 52, 75, 104, 130 and 156 the proportion of progression-free patients will be estimated with a 95% confidence interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median PFS</measure>
    <time_frame>up to 156 weeks</time_frame>
    <description>At weeks 26, 52, 75, 104, 130 and 156 the median PFS will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>up to 156 weeks</time_frame>
    <description>At weeks 26, 52, 75, 104, 130 and 156 the proportion of patients surviving will be estimated with a 95% confidence interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median OS</measure>
    <time_frame>up to 156 weeks</time_frame>
    <description>At weeks 26, 52, 75, 104, 130 and 156 the median survival will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessment</measure>
    <time_frame>Quality of life questionnaires will be completed by the patients at baseline, after 3 months of therapy, after 6 months of treatment (end of treatment) and finally 3 months after therapy.</time_frame>
    <description>Quality of life as measured by FACT-Cx questionnaire for the cervical cancer group and by the FACT-G questionnaire for the endometrial carcinoma and uterine sarcoma group. Descriptive statistics of the total score at each visit and the difference with the baseline visit for all other visits will be reported.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Cervical Cancer</condition>
  <condition>Endometrial Cancer</condition>
  <condition>Uterine Cancer</condition>
  <arm_group>
    <arm_group_label>experimental arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pembrolizumab, immune modulatory cocktail composed of Vitamin D, Lansoprazole Teva, Cyclophosphamide and Aspirine, radiation and Curcumin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Efficacy of the combined treatment</description>
    <arm_group_label>experimental arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation</intervention_name>
    <description>Efficacy of the combined treatment</description>
    <arm_group_label>experimental arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>Efficacy of the combined treatment</description>
    <arm_group_label>experimental arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Efficacy of the combined treatment</description>
    <arm_group_label>experimental arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lansoprazole</intervention_name>
    <description>Efficacy of the combined treatment</description>
    <arm_group_label>experimental arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Efficacy of the combined treatment</description>
    <arm_group_label>experimental arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Curcumin</intervention_name>
    <description>Efficacy of the combined treatment</description>
    <arm_group_label>experimental arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have histologically confirmed endometrial carcinoma, cervical carcinoma or uterine&#xD;
             sarcoma, refractory or persistent to chemotherapy or recurrent disease after at least&#xD;
             one line of chemotherapy.&#xD;
&#xD;
          -  Presence of an index lesion amenable to hypofractionated stereotactic radiotherapy&#xD;
&#xD;
          -  At least one lesion outside the radiation field that can be followed by imaging for&#xD;
             clinical response according to RECIST and irRC&#xD;
&#xD;
          -  Be willing to provide tissue from a newly obtained core or excisional biopsy of a&#xD;
             tumor lesion before and after radiotherapy if technically feasible.&#xD;
&#xD;
          -  Have a performance status of 0 or 1 or 2 on the ECOG Performance Scale.&#xD;
&#xD;
          -  Demonstrate adequate organ function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently participating and receiving study therapy or has participated in a study of&#xD;
             an investigational agent and received study therapy or used an investigational device&#xD;
             within 4 weeks of the first dose of treatment.&#xD;
&#xD;
          -  Prior treatment with anti-PD-1, anti-PD-L1, anti-PD-L2 agent&#xD;
&#xD;
          -  Diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other&#xD;
             form of immunosuppressive therapy within 2 weeks prior to the first dose of trial&#xD;
             treatment,&#xD;
&#xD;
          -  Known history of active TB (Bacillus Tuberculosis), Human Immunodeficiency Virus&#xD;
             (HIV), HTLV or syphilis,non-infectious pneumonitis, has active autoimmune disease.&#xD;
&#xD;
          -  Has active central nervous system metastases and/or carcinomatous meningitis&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hannelore Denys, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Ghent</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Antwerp</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CMSE Namur</name>
      <address>
        <city>Namur</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>May 29, 2017</study_first_submitted>
  <study_first_submitted_qc>June 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2017</study_first_posted>
  <last_update_submitted>September 6, 2021</last_update_submitted>
  <last_update_submitted_qc>September 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunotherapy</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Immune-modulatory cocktail</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Uterine Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Curcumin</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Lansoprazole</mesh_term>
    <mesh_term>Dexlansoprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

